NOT-HL-23-103: Notice of Correction to Application Instructions for RFA-HL-24-007 Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Data Coordinating Center (U24- Clinical Trial Not Allowed)

Notice of Correction to Application Instructions for RFA-HL-24-007 Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Data Coordinating Center (U24- Clinical Trial Not Allowed)

Notice Number:

NOT-HL-23-103

Key Dates

Release Date:

July 24, 2023

Related Announcements

.July 14, 2023 - Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Data Coordinating Center (U24- Clinical Trial Not Allowed). See NOFO RFA-HL-24-007.

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

On July 14, 2023, the NHLBI published RFA-HL-24-007 Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Data Coordinating Center (U24- Clinical Trial Not Allowed). The purpose of this Notice is to inform applicants that information regarding requests for direct costs of $500,000 or more in any given year are not relevant to RFA-HL-24-007. The following information is therefore removed from Section IV. Application and Submission Information.

Section IV. Application and Submission Information

7. Other Submission Requirements and Information

Requests of $500,000 or more for direct costs in any year

Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application and follow the Policy on the Acceptance for Review of Unsolicited Applications that Request $500,000 or More in Direct Costs as described in the SF424 (R&R) Application Guide.

All other aspects of RFA-HL-24-007 remain unchanged.

Inquiries

Please direct all inquiries to:

Scientific/Research Contact(s)

Qing "Sara" Lin, Ph.D.
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0222
Email: sara.lin@nih.gov